Combine and conquer: challenges for targeted therapy combinations in early phase trials
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 14, Issue 1, Pages 57-66
Publisher
Springer Nature
Online
2016-07-05
DOI
10.1038/nrclinonc.2016.96
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictive Biomarkers for Anti-Epidermal Growth Factor Receptor Therapy: BeyondKRASTesting
- (2017) Noman Ashraf et al. Journal of the National Comprehensive Cancer Network
- Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
- (2015) A. Stewart et al. ANNALS OF ONCOLOGY
- Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
- (2015) L. Apetoh et al. ANNALS OF ONCOLOGY
- HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
- (2015) Pooja P Advani et al. Biomarkers in Medicine
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts
- (2015) J. W. Cassidy et al. CANCER RESEARCH
- Toxicology Strategies for Drug Discovery: Present and Future
- (2015) Eric A. G. Blomme et al. CHEMICAL RESEARCH IN TOXICOLOGY
- MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
- (2015) C. Garcia-Garcia et al. CLINICAL CANCER RESEARCH
- Translational Implications of Tumor Heterogeneity
- (2015) M. Jamal-Hanjani et al. CLINICAL CANCER RESEARCH
- Drugging PI3K in cancer: refining targets and therapeutic strategies
- (2015) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
- (2015) Han Kiat Ho et al. DRUG METABOLISM REVIEWS
- Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer
- (2015) Rachel N. Grisham et al. JOURNAL OF CLINICAL ONCOLOGY
- Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer.
- (2015) Rona D. Yaeger et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap
- (2015) David R. Gandara et al. JOURNAL OF CLINICAL ONCOLOGY
- ExpandedRAS: Refining the Patient Population
- (2015) Chloe E. Atreya et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
- (2015) Stephen R. D. Johnston JNCI-Journal of the National Cancer Institute
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
- (2015) Jean Jacques Grob et al. LANCET ONCOLOGY
- Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
- (2015) Junwei Shi et al. NATURE BIOTECHNOLOGY
- High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
- (2015) Hui Gao et al. NATURE MEDICINE
- Pathway and network analysis of cancer genomes
- (2015) NATURE METHODS
- The influence of subclonal resistance mutations on targeted cancer therapy
- (2015) Michael W. Schmitt et al. Nature Reviews Clinical Oncology
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint modulation: Rational design of combination strategies
- (2015) Dmitriy Zamarin et al. PHARMACOLOGY & THERAPEUTICS
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
- (2015) E. M. Tricker et al. Cancer Discovery
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- Systems biology approaches for advancing the discovery of effective drug combinations
- (2015) Karen A Ryall et al. Journal of Cheminformatics
- Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
- (2015) Timothy J. Stuhlmiller et al. Cell Reports
- Distinctive Behaviors of Druggable Proteins in Cellular Networks
- (2015) Costas Mitsopoulos et al. PLoS Computational Biology
- Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells
- (2015) Anil Korkut et al. eLife
- Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
- (2015) Stephen R. D. Johnston JNCI-Journal of the National Cancer Institute
- Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays
- (2015) Jonathan A. Lee et al. PLoS One
- The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
- (2014) Christina Therkildsen et al. ACTA ONCOLOGICA
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
- (2014) L. R. Molife et al. CLINICAL CANCER RESEARCH
- Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
- (2014) N. A. O'Brien et al. CLINICAL CANCER RESEARCH
- Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
- (2014) A. W. Tolcher et al. CLINICAL CANCER RESEARCH
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- (2014) Rituparna Das et al. JOURNAL OF IMMUNOLOGY
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
- (2014) Antoni Ribas et al. LANCET ONCOLOGY
- Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models
- (2014) T. Smyth et al. MOLECULAR CANCER THERAPEUTICS
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- RNAi screening comes of age: improved techniques and complementary approaches
- (2014) Stephanie E. Mohr et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Applying Synthetic Lethality for the Selective Targeting of Cancer
- (2014) Donal P. McLornan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer
- (2014) Geraldine Perkins et al. PHARMACOGENOMICS
- HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models
- (2014) Luke Whitesell et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma
- (2014) Marian M. Deuker et al. Cancer Discovery
- Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy
- (2014) H. Al-Ahmadie et al. Cancer Discovery
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
- (2013) Shirish M. Gadgeel et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
- (2013) Carolyn D. Britten CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
- (2013) E. Romano et al. CLINICAL CANCER RESEARCH
- A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
- (2013) D. A. Reardon et al. CLINICAL CANCER RESEARCH
- Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors
- (2013) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetics and biomarkers in personalisation of lung cancer treatment
- (2013) Rafael Rosell et al. LANCET
- The causes and consequences of genetic heterogeneity in cancer evolution
- (2013) Rebecca A. Burrell et al. NATURE
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Safety and feasibility of targeted agent combinations in solid tumours
- (2013) Sook Ryun Park et al. Nature Reviews Clinical Oncology
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
- (2013) M. Pourdehnad et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Systems Pharmacology of Adverse Event Mitigation by Drug Combinations
- (2013) S. Zhao et al. Science Translational Medicine
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- A Systems Biology Approach to Personalizing Therapeutic Combinations
- (2013) L. N. Kwong et al. Cancer Discovery
- Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
- (2013) M. T. Herrera-Abreu et al. Cancer Discovery
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy
- (2013) D. B. Johnson et al. Cancer Immunology Research
- The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
- (2012) Madhu S. Kumar et al. CELL
- Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
- (2012) Michael Steckel et al. CELL RESEARCH
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
- (2012) Maja J. A. de Jonge et al. INVESTIGATIONAL NEW DRUGS
- It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
- (2012) J. R. Westin et al. MOLECULAR CANCER THERAPEUTICS
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Combinatorial drug therapy for cancer in the post-genomic era
- (2012) Bissan Al-Lazikani et al. NATURE BIOTECHNOLOGY
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- Patient-derived tumour xenografts as models for oncology drug development
- (2012) John J. Tentler et al. Nature Reviews Clinical Oncology
- Evolution of the cancer genome
- (2012) Lucy R. Yates et al. NATURE REVIEWS GENETICS
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
- (2012) Matthew A. Held et al. Cancer Discovery
- Targeting IGF-1R: throwing out the baby with the bathwater?
- (2011) B Basu et al. BRITISH JOURNAL OF CANCER
- Mutant BRAF Melanomas—Dependence and Resistance
- (2011) Poulikos I. Poulikakos et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
- (2011) Vinod P Balachandran et al. NATURE MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis
- (2010) S. Iadevaia et al. CANCER RESEARCH
- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
- (2009) L. M. Ellis et al. CLINICAL CANCER RESEARCH
- From Theoretical Synergy to Clinical Supra-Additive Toxicity
- (2009) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Models from experiments: combinatorial drug perturbations of cancer cells
- (2008) Sven Nelander et al. Molecular Systems Biology
- Harnessing genetically engineered mouse models for preclinical testing
- (2007) Ana I. Robles et al. CHEMICO-BIOLOGICAL INTERACTIONS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now